Skip to main content
Biomark Diagnostics Inc. logo

Biomark Diagnostics Inc. — Investor Relations & Filings

Ticker · BUX LEI · 529900UHZ378KKXOLY69 CSE Professional, scientific and technical activities
Filings indexed 142 across all filing types
Latest filing 2023-08-29 Regulatory Filings
Country CA Canada
Listing CSE BUX

About Biomark Diagnostics Inc.

https://www.biomarkdiagnostics.com/

Biomark Diagnostics Inc. is an oncology-focused company developing advanced liquid biopsy diagnostic technologies for the early detection, monitoring, and screening of cancer. The core technology platform utilizes metabolomics, the study of biomarkers and metabolites, integrated with Artificial Intelligence and Machine Learning algorithms. This approach aims to provide rapid, accurate results for hard-to-detect cancers, thereby improving patient outcomes. The company's pipeline includes the Liquid Biopsy SSAT1 Assay and a Metabolic Panel.

Recent filings

Filing Released Lang Actions
Interim MD&A - English.pdf
Regulatory Filings
2023-08-29 English
Interim financial statements/report – English.pdf
Regulatory Filings
2023-08-29 English
News release - English.pdf
Regulatory Filings
2023-08-08 English
52-109FV1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings
2023-07-31 English
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings
2023-07-31 English
Annual MD&A - English.pdf
Regulatory Filings
2023-07-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.